Nektar Therapeutics annual capital expenditures (capex)
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Nektar Therapeutics Capital Expenditures (CapEx) Growth & History (NKTR)
Nektar Therapeutics's capital expenditures (capex) was $171,000 for fiscal 2025.
View full Nektar Therapeutics company overviewNektar Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $171,000 | −$1.3M | −88.35% |
| 2024 | 2024-12-31 | $1.5M | $603,000 | +69.71% |
| 2023 | 2023-12-31 | $865,000 | −$4.8M | −84.76% |
| 2022 | 2022-12-31 | $5.7M | −$9.3M | −62.13% |
| 2021 | 2021-12-31 | $15.0M | $7.7M | +106.52% |
| 2020 | 2020-12-31 | $7.3M | −$19.0M | −72.39% |
| 2019 | 2019-12-31 | $26.3M | $12.0M | +84.60% |
| 2018 | 2018-12-31 | $14.2M | $4.6M | +47.16% |
| 2017 | 2017-12-31 | $9.7M | $3.3M | +51.38% |
| 2016 | 2016-12-31 | $6.4M | −$4.8M | −42.90% |
| 2015 | 2015-12-31 | $11.2M | $1.2M | +12.22% |
| 2014 | 2014-12-31 | $10.0M | $5.9M | +143.85% |
| 2013 | 2013-12-31 | $4.1M | −$6.5M | −61.34% |
| 2012 | 2012-12-31 | $10.6M | $861,000 | +8.86% |
| 2011 | 2011-12-31 | $9.7M | −$21.7M | −69.09% |
| 2010 | 2010-12-31 | $31.5M | $15.1M | +91.93% |
| 2009 | 2009-12-31 | $16.4M | — | — |
Nektar Therapeutics quarterly capital expenditures (capex)
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $94,000 | $57,000 | +154.05% |
| Q1 2026 | 2026-03-31 | $18,000 | $16,000 | +800.00% |
| Q4 2025 | 2025-12-31 | $18,000 | −$441,000 | −96.08% |
| Q3 2025 | 2025-09-30 | $114,000 | −$552,000 | −82.88% |
| Q2 2025 | 2025-06-30 | $37,000 | −$149,000 | −80.11% |
| Q1 2025 | 2025-03-31 | $2,000 | −$155,000 | −98.73% |
| Q4 2024 | 2024-12-31 | $459,000 | $222,000 | +93.67% |
| Q3 2024 | 2024-09-30 | $666,000 | $633,000 | +1918.18% |
| Q2 2024 | 2024-06-30 | $186,000 | $24,000 | +14.81% |
| Q1 2024 | 2024-03-31 | $157,000 | −$276,000 | −63.74% |
| Q4 2023 | 2023-12-31 | $237,000 | −$275,000 | −53.71% |
| Q3 2023 | 2023-09-30 | $33,000 | −$148,000 | −81.77% |
| Q2 2023 | 2023-06-30 | $162,000 | −$618,000 | −79.23% |
| Q1 2023 | 2023-03-31 | $433,000 | −$3.8M | −89.70% |
| Q4 2022 | 2022-12-31 | $512,000 | −$5.4M | −91.32% |
| Q3 2022 | 2022-09-30 | $181,000 | −$2.8M | −93.84% |
| Q2 2022 | 2022-06-30 | $780,000 | −$2.5M | −76.23% |
| Q1 2022 | 2022-03-31 | $4.2M | $1.3M | +46.14% |
| Q4 2021 | 2021-12-31 | $5.9M | $4.1M | +236.15% |
| Q3 2021 | 2021-09-30 | $2.9M | $1.0M | +53.72% |
| Q2 2021 | 2021-06-30 | $3.3M | $587,000 | +21.79% |
| Q1 2021 | 2021-03-31 | $2.9M | $2.0M | +219.56% |
| Q4 2020 | 2020-12-31 | $1.8M | −$1.9M | −52.22% |
| Q3 2020 | 2020-09-30 | $1.9M | −$3.4M | −64.12% |
| Q2 2020 | 2020-06-30 | $2.7M | −$8.9M | −76.86% |
| Q1 2020 | 2020-03-31 | $900,000 | −$4.7M | −84.07% |
| Q4 2019 | 2019-12-31 | $3.7M | −$5.0M | −57.74% |
| Q3 2019 | 2019-09-30 | $5.3M | $3.5M | +192.15% |
| Q2 2019 | 2019-06-30 | $11.6M | $8.9M | +324.15% |
| Q1 2019 | 2019-03-31 | $5.6M | $4.7M | +473.40% |
| Q4 2018 | 2018-12-31 | $8.7M | $6.3M | +263.02% |
| Q3 2018 | 2018-09-30 | $1.8M | $883,000 | +94.04% |
| Q2 2018 | 2018-06-30 | $2.7M | $490,000 | +21.73% |
| Q1 2018 | 2018-03-31 | $985,000 | −$3.1M | −75.91% |
| Q4 2017 | 2017-12-31 | $2.4M | −$258,000 | −9.73% |
| Q3 2017 | 2017-09-30 | $939,000 | $432,000 | +85.21% |
| Q2 2017 | 2017-06-30 | $2.3M | $700,000 | +45.02% |
| Q1 2017 | 2017-03-31 | $4.1M | $2.4M | +143.54% |
| Q4 2016 | 2016-12-31 | $2.7M | $178,000 | +7.20% |
| Q3 2016 | 2016-09-30 | $507,000 | −$3.6M | −87.75% |
| Q2 2016 | 2016-06-30 | $1.6M | −$2.0M | −55.89% |
| Q1 2016 | 2016-03-31 | $1.7M | $620,000 | +58.55% |
| Q4 2015 | 2015-12-31 | $2.5M | −$1.4M | −36.36% |
| Q3 2015 | 2015-09-30 | $4.1M | $3.2M | +360.80% |
| Q2 2015 | 2015-06-30 | $3.5M | $2.9M | +427.69% |
| Q1 2015 | 2015-03-31 | $1.1M | −$3.5M | −76.59% |
| Q4 2014 | 2014-12-31 | $3.9M | $1.2M | +43.45% |
| Q3 2014 | 2014-09-30 | $898,000 | $310,000 | +52.72% |
| Q2 2014 | 2014-06-30 | $668,000 | $190,000 | +39.75% |
| Q1 2014 | 2014-03-31 | $4.5M | $4.2M | +1331.65% |
| Q4 2013 | 2013-12-31 | $2.7M | −$2.1M | −44.02% |
| Q3 2013 | 2013-09-30 | $588,000 | −$2.0M | −77.14% |
| Q2 2013 | 2013-06-30 | $478,000 | −$1.2M | −71.14% |
| Q1 2013 | 2013-03-31 | $316,000 | −$1.2M | −79.16% |
| Q4 2012 | 2012-12-31 | $4.8M | $3.4M | +238.87% |
| Q3 2012 | 2012-09-30 | $2.6M | $1.1M | +77.50% |
| Q2 2012 | 2012-06-30 | $1.7M | −$1.4M | −46.23% |
| Q1 2012 | 2012-03-31 | $1.5M | −$2.2M | −59.73% |
| Q4 2011 | 2011-12-31 | $1.4M | −$7.9M | −84.64% |
| Q3 2011 | 2011-09-30 | $1.4M | −$11.9M | −89.16% |
| Q2 2011 | 2011-06-30 | $3.1M | −$1.7M | −36.14% |
| Q1 2011 | 2011-03-31 | $3.8M | −$208,000 | −5.24% |
| Q4 2010 | 2010-12-31 | $9.3M | — | — |
| Q3 2010 | 2010-09-30 | $13.4M | — | — |
| Q2 2010 | 2010-06-30 | $4.8M | — | — |
| Q1 2010 | 2010-03-31 | $4.0M | — | — |
Nektar Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Nektar Therapeutics's capital expenditures (capex) decreased from $7.3M to $171,000, a change of −$7.1M. The latest reported quarter, Q2 2026, shows $94,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nektar Therapeutics source filings ↗